What Is Uveal Melanoma and How Do Families Plan for End of Life?
By CRYSTAL BAI •
The short answer: Uveal melanoma is the most common primary eye cancer in adults. Despite effective local treatment, up to 50% of patients develop metastatic disease — primarily to the liver — with a very poor prognosis. Early palliative care and end-of-life planning are critical when metastases are detected.
Understanding Uveal Melanoma
Uveal melanoma arises in the uveal tract of the eye (iris, ciliary body, or choroid). Local treatment — radiation plaque therapy or enucleation — is highly effective for primary tumors. However, metastasis, which occurs in up to 50% of patients, is almost exclusively to the liver and carries a median survival of 4–15 months.
The Challenge of Metastatic Uveal Melanoma
Unlike cutaneous melanoma, uveal melanoma responds poorly to immune checkpoint inhibitors. Tebentafusp (kimmtrak) — a bispecific T cell engager targeting gp100 — is FDA-approved for HLA-A*02:01-positive metastatic uveal melanoma, offering improved overall survival in this subset.
Liver-Directed Therapies in the Palliative Setting
Hepatic intra-arterial therapy (HIAT), percutaneous hepatic perfusion (PHP), and ablation can provide liver-specific disease control. These approaches aim to extend life and maintain liver function rather than achieve cure.
End-of-Life Planning for Uveal Melanoma Families
The often-sudden shift from "I had eye cancer treated years ago" to metastatic disease is deeply disorienting for patients and families. Death doulas and palliative care teams help bridge this gap — supporting rapid advance care planning and emotional preparation.
Frequently Asked Questions
What is the survival rate for metastatic uveal melanoma?
Median overall survival for metastatic uveal melanoma is 4–15 months, depending on treatment. Tebentafusp (kimmtrak) improves survival in HLA-A*02:01-positive patients.
Why is uveal melanoma hard to treat when it spreads?
Uveal melanoma has a different molecular profile from skin melanoma and does not respond well to the checkpoint inhibitors (pembrolizumab, nivolumab) that work for cutaneous melanoma.
Can a death doula help with uveal melanoma end-of-life planning?
Yes — death doulas help uveal melanoma patients and families navigate the shock of late metastatic diagnosis, compress advance care planning timelines, and provide emotional presence through a difficult journey.
Are there clinical trials for metastatic uveal melanoma?
Yes — clinical trials are ongoing at major cancer centers. The Ocular Melanoma Foundation (ocularmelanoma.org) is a patient resource for trial information and support.
Renidy connects grieving families with compassionate death doulas and AI-powered funeral planning tools. Try our free AI funeral planner or find a death doula near you.